Doctomatic Makes the International Leap and Takes Its Technology to Mexico and Brazil

Doctomatic starts its international adventure on the other side of the ocean. The Spanish company, owned by the co-founder of Doctoralia, Frederic Llordachs, has made its first international leap in Mexico and Brazil, as confirmed by the executive.

The company specializing in digital health is currently working on pilot projects in both Latin American countries, with the aim of consolidating digital health initiatives for chronic patients by 2023. For its arrival in Mexico, the company has added Christopher Barreda to its team as head of business development.

The Doctomatic signee has a degree in Marketing from Isec Business University and comes from Clivi Health, a Mexican company specializing in the diabetes sector, where he has worked as a health consultant and in the sales area.

Read more about Doctomatic and find the latest business news of the day with the Born2Invest mobile app.

Doctomatic aims to consolidate digital health initiatives in the two countries this year

In the sales area, Barreda worked looking for company alliances with podiatrists and ophthalmologists, with the aim of strengthening the service offered to the patient with diabetes by providing the services of Clivi Health.

In addition to working for the Mexican company, the new Doctomatic recruit was also responsible for follow-up and attention to corporate clients and hospitals at Life in Genomics, a Mexican biotechnology company that offers genetic studies for hereditary cancer, prenatal studies through fetal DNA, and exomes, among others. Barreda was also a commercial advisor at Cryo-Cell, where he was responsible for promoting the service with gynecology specialists and direct sales to patients.

In Brazil, the company has added Vitor Oliveira to its team as head of business development in the country. Oliveira holds a degree in Chemistry from the Instituto Federal do Rio de Janeiro and an MBA in Management and Global Marketing from the Universidade de Sao Paulo.

Before joining Doctomatic, Oliveira worked for Feegow Clinic as head of sales, was CEO and co-founder of Medicion, a software developed for medical offices, as well as director of sales operations at GPro Negócios.

The Spanish company aims to reach ‘break even’ in 2023

Doctomatic was created a little over a year ago with the objective of offering a digital platform for the remote management and control of chronic patients. The company has raised €415,000 with the support of Carlos Blanco and Oriol Juncosa, both from the Encomenda Smart Capital fund, and Ship2B Ventures, a venture capital firm that invests in startups with high social and environmental impact.

Doctomatic uses artificial intelligence (AI) capable of reading data from images to know whether a person may or may not have a disease. The company’s clients include hospitals, doctors, and insurance companies. Doctomatic’s forecast is to reach break-even in 2023 and in a matter of five years to reach five million patients and a turnover of more than €20 million.

The company already has agreements with the Suara cooperative to monitor patients with diabetes, hypertension, obesity, or respiratory problems. It is also working with the Korian Spain group of homes for the elderly to monitor remote medicalization, as well as with the Hospital del Mar in Barcelona to monitor patients with heart failure.

__

(Featured image by Tumisu via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.